Arvinas Inc (ARVN) Stock Price, Quote & News

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders f...

Industry: Biotechnology

Sector: Healthcare

Phone: 203 535 1456

Website: www.arvinas.com

Address:

5 Science Park, 395 Winchester Avenue, New Haven, United States

buyandsold Nov. 13 at 3:05 PM

$ARVN is an executive travel club to conferences where they embarrass themselves talking up "financial asset" "best in class" Vepdeg. Run buy a CEO who draws millions in salary half a year after he said he was retiring. Why retire if someone pays you to keep warm at a fire buring investor cash? Dont worry though, the pipeline has some bangers nearly as good as Vepdeg.

0 · Reply

Greatguns Nov. 12 at 6:44 PM

$ARVN Acadian Asset Management LLC Purchases 1,267,593 Shares of Arvinas, Inc.,,https://www.marketbeat.com/instant-alerts/filing-acadian-asset-management-llc-purchases-1267593-shares-of-arvinas-inc-arvn-2025-11-12/

0 · Reply

AnomalyDetective Nov. 11 at 2:16 PM

$ARVN (Week 46 MDA) pick for members becomes the first of four selections to break 10% gains through Monday. This stock could accelerate rapidly to fill the gap to 16/share. ✅ Extending the count to 345 weeks with at least one pick gaining over 10% in less than a week for members: https://seekingalpha.com/mp/1201-value-momentum-breakouts ✅ Govt reopening is fueling the rally with many prior MDA breakout picks: http://top.vmbreakouts.com moving sharply higher @vmbreakouts

0 · Reply

Escapee Nov. 10 at 5:11 PM

$ARVN once again into the gap territory… this one closes north of $15

1 · Reply

AnomalyDetective Nov. 10 at 3:03 PM

0 · Reply

JarvisFlow Nov. 10 at 2:14 PM

Stephens & Co. has updated their rating for Arvinas ( $ARVN ) to Overweight with a price target of 15.

0 · Reply

StockConsultant Nov. 10 at 1:48 AM

$ARVN Arvinas stock, nice top of range breakout at https://stockconsultant.com/?ARVN

0 · Reply

JarvisFlow Nov. 6 at 3:41 PM

Wells Fargo updates rating for Arvinas ( $ARVN ) to Overweight, target set at 16 → 15.

0 · Reply

Nguyentt Nov. 6 at 3:18 PM

$ARVN 12

1 · Reply

JarvisFlow Nov. 6 at 2:27 PM

Barclays has updated their rating for Arvinas ( $ARVN ) to Overweight with a price target of 16.

0 · Reply

Arvinas, Inc. (ARVN) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 7:00 AM EST - 9 days ago

Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 3, 2025, 4:00 PM EST - 11 days ago

Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting

Nov 3, 2025, 7:00 AM EST - 11 days ago

Arvinas to Participate in Upcoming Investor Conferences

Oct 29, 2025, 7:00 AM EDT - 16 days ago

Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 24, 2025, 4:00 PM EDT - 21 days ago

Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 22, 2025, 4:00 PM EDT - 23 days ago

Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 20, 2025, 4:15 AM EDT - 25 days ago

Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

PFE

Oct 13, 2025, 7:00 AM EDT - 4 weeks ago

Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress

Oct 5, 2025, 2:00 PM EDT - 5 weeks ago

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 1, 2025, 7:00 AM EDT - 6 weeks ago

Arvinas to Present Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Sep 17, 2025, 5:50 PM EDT - 2 months ago

Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party

PFE

Sep 17, 2025, 4:30 PM EDT - 2 months ago

Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation

Sep 9, 2025, 10:12 AM EDT - 2 months ago

Arvinas, Inc. (ARVN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Aug 8, 2025, 4:05 PM EDT - 3 months ago

Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

Aug 6, 2025, 1:24 PM EDT - 3 months ago

Arvinas, Inc. (ARVN) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 3 months ago

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 4:05 PM EDT - 3 months ago

Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 9, 2025, 7:00 AM EDT - 4 months ago

Arvinas Announces Retirement of Chief Executive Officer and Succession Plan

Jun 13, 2025, 7:00 AM EDT - 5 months ago

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

Jun 6, 2025, 7:00 AM EDT - 5 months ago

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

Jun 5, 2025, 8:28 AM EDT - 5 months ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

May 31, 2025, 8:06 AM EDT - 5 months ago

Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression

PFE

May 31, 2025, 8:00 AM EDT - 5 months ago

Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer

May 30, 2025, 7:00 AM EDT - 6 months ago

Arvinas to Present at Jefferies Global Healthcare Conference

May 16, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

May 15, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

May 14, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Shareholders to Reach Out

May 13, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 6 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 9, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

May 8, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

May 7, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation

May 6, 2025, 10:00 AM EDT - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out

buyandsold Nov. 13 at 3:05 PM

0 · Reply

Greatguns Nov. 12 at 6:44 PM

0 · Reply

AnomalyDetective Nov. 11 at 2:16 PM

0 · Reply

Escapee Nov. 10 at 5:11 PM

$ARVN once again into the gap territory… this one closes north of $15

1 · Reply

AnomalyDetective Nov. 10 at 3:03 PM

0 · Reply

JarvisFlow Nov. 10 at 2:14 PM

Stephens & Co. has updated their rating for Arvinas ( $ARVN ) to Overweight with a price target of 15.

0 · Reply

StockConsultant Nov. 10 at 1:48 AM

$ARVN Arvinas stock, nice top of range breakout at https://stockconsultant.com/?ARVN

0 · Reply

JarvisFlow Nov. 6 at 3:41 PM

Wells Fargo updates rating for Arvinas ( $ARVN ) to Overweight, target set at 16 → 15.

0 · Reply

Nguyentt Nov. 6 at 3:18 PM

$ARVN 12

1 · Reply

JarvisFlow Nov. 6 at 2:27 PM

Barclays has updated their rating for Arvinas ( $ARVN ) to Overweight with a price target of 16.

0 · Reply

d_risk Nov. 5 at 9:23 PM

$ARVN - Arvinas Inc. Common Stock - 10Q - Updated Risk Factors ARVN’s latest risk update spotlights major 2025 workforce cuts, leadership turnover, FDA and political disruptions impacting clinical and regulatory timelines, a new share repurchase program with limited obligations, and sharpened focus on select R&D amid resource constraints—all potentially affecting future revenue, portfolio strategy, and commercialization. #Biotechnology #R&DFocus #LeadershipTurnover #RegulatoryRisk #WorkforceReduction 🟢 Added 🟠 Removed https://d-risk.ai/ARVN/10-Q/2025-11-05

0 · Reply

TwongStocks Nov. 5 at 1:29 PM

$ARVN Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update https://www.globenewswire.com/news-release/2025/11/05/3181298/0/en/Arvinas-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html Cash runway into 2H 2028

0 · Reply

Thestocktraderhubzee Nov. 5 at 12:07 PM

$ARVN Arvinas Q3 EPS $(0.48) Beats $(0.81) Estimate, Sales $41.900M Beat $23.600M Estimate

0 · Reply

Greatguns Nov. 3 at 10:24 PM

$ARVN Arvinas Holding Company (ARVN) Gets a Buy from BTIG..maintained a Buy rating on Arvinas Holding Company today and set a price target of $14.00. The company’s shares opened today at $10.14....https://www.tipranks.com/news/blurbs/arvinas-holding-company-arvn-gets-a-buy-from-btig-blurbs?utm_source=zacks.com&utm_medium=referral

0 · Reply

diegosan21 Nov. 3 at 3:41 PM

$SRPT $ARWR $ARVN my pharmas all in red today, Let's buy more

0 · Reply

SaluteYourShorts Oct. 30 at 2:23 PM

$ARVN noice

0 · Reply

SaluteYourShorts Oct. 29 at 3:20 PM

$CARR $NESR $ARVN only things I've bought today

1 · Reply

SaluteYourShorts Oct. 29 at 2:49 PM

$ARVN still hitting w massive prints

1 · Reply

TwongStocks Oct. 29 at 11:31 AM

$ARVN Q3 earnings call confirmed Nov 5 at 8:00am ET https://ir.arvinas.com/events/event-details/arvinas-3q25-earnings-call

0 · Reply

outlawinvestor1 Oct. 28 at 4:35 PM

$FHTX great time to come into foghorn. tpd landscape is growing! only a matter of time before lilly buys this one. $GLUE $CCCC $ARVN $PRLD

0 · Reply

outlawinvestor1 Oct. 26 at 11:57 AM

$CCCC nice updated overview of the tpd landscape. $ARVN $NRIX $GLUE $KYMR

1 · Reply

Thestocktraderhubzee Oct. 23 at 10:03 AM

WATCHLIST OCT 23 2025. $BURU Nuburu shares are trading higher after the company entered into a strategic framework agreement with Nuburu Defense and Maddox Defense to establish a joint venture company. $ARVN Arvinas To Present Preclinical Data For ARV-806 At 2025 At AACR-NCI-EORTC International Conference In Boston $HON Honeywell International Expects To Complete Separation Of Solstice Advanced Materials Business On Oct. 30, Aerospace Technologies Operations In H2 2026 $SLMT Solmate Infrastructure Provides Update On Its Validator Operations, Data Center Selection, M&A Strategy, And $300M Oversubscribed Pipe Financing And Plans To File The Registration Statement For Pipe Investor Shares By November 22, 2025 $GPUS Hyperscale Data Announces Intent To Launch On-Demand NVIDIA Graphics Processing Unit Cloud Platform From Michigan AI Data Center Campus

0 · Reply

Market Cap	668.57M
Revenue (ttm)	263.40M
Net Income (ttm)	-198.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-75.51%
Debt to Equity Ratio	0.00

Volume	2,455,600
Avg Vol	2,339,554
Day's Range	N/A - N/A
Shares Out	64.22M
Stochastic %K	38%
Beta	2.38
Analysts	Sell
Price Target	$12.20